STEFANIE SPENCE: Open Payments
NPI 1487046751 · DECATUR, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$681 in 30 payments from 13 companies in 2025. Trend: 2023 $268 · 2024 $754 · 2025 $681
Food & beverage: $681
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $131 |
| AKEBIA THERAPEUTICS INC | 4 | $109 |
| Calliditas Therapeutics US Inc. | 3 | $86 |
| AstraZeneca Pharmaceuticals LP | 4 | $77 |
| Novartis Pharmaceuticals Corporation | 2 | $58 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $50 |
| Novo Nordisk Inc | 2 | $48 |
| Travere Therapeutics, Inc. | 1 | $27 |
| SERVIER PHARMACEUTICALS LLC | 1 | $27 |
| Merck Sharp & Dohme LLC | 1 | $21 |
Products named: JARDIANCE, TARPEYO, Auryxia, Fabhalta, Kerendia, Ozempic, IMFINZI, FARXIGA.
Industry payments across AL — which companies pay providers there.
